107430-66-0
Chemical Structure
CD1530
- CAS No.: 107430-66-0
- Formula:C27H26O3
- Molecular Weight:398.49
IUPAC Name: 4-(7-(adamantan-1-yl)-6-hydroxynaphthalen-2-yl)benzoic acid
InChIKey: VCQGNUWOMLYNNG-UHFFFAOYSA-N
SMILES: O=C(O)C1=CC=C(C2=CC=C3C=C(O)C(C4(C5)CC6CC5CC(C6)C4)=CC3=C2)C=C1
Biological Activity: CD1530 is an orally active, selective RARγ agonist and antibacterial agent. CD1530 reduces Smad1/5/8 phosphorylation and overall Smad levels. CD1530 reduces β-catenin, MMP9 protein, and ROS levels. CD1530 exhibits activities such as inhibiting heterotopic ossification, promoting Achilles tendon healing, and inhibiting muscle fatty infiltration. CD1530 can be used in the research of orthopedic diseases (such as heterotopic ossification, Achilles tendon injury), muscle diseases (such as muscle fatty infiltration-related diseases)[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CD1530 | 98.01% | CD1530 is an orally active, selective RARγ agonist and antibacterial agent. CD1530 reduces Smad1/5/8 phosphorylation and overall Smad levels. CD1530 reduces β-catenin, MMP9 protein, and ROS levels. CD1530 exhibits activities such as inhibiting heterotopic ossification, promoting Achilles tendon healing, and inhibiting muscle fatty infiltration. CD1530 can be used in the research of orthopedic diseases (such as heterotopic ossification, Achilles tendon injury), muscle diseases (such as muscle fatty infiltration-related diseases). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CD1530 (Standard) | ≥98% | CD1530 (Standard) is the analytical standard of CD1530 (HY-108527). This product is intended for research and analytical applications. CD1530 is an orally active, selective RARγ agonist and antibacterial agent. CD1530 reduces Smad1/5/8 phosphorylation and overall Smad levels. CD1530 reduces β-catenin, MMP9 protein, and ROS levels. CD1530 exhibits activities such as inhibiting heterotopic ossification, promoting Achilles tendon healing, and inhibiting muscle fatty infiltration. CD1530 can be used in the research of orthopedic diseases (such as heterotopic ossification, Achilles tendon injury), muscle diseases (such as muscle fatty infiltration-related diseases). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Shimono K, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. Nat Med. 2011 Apr;17(4):454-60. [Content Brief]
- [2]. Murholm M, et al. Retinoic acid has different effects on UCP1 expression in mouse and human adipocytes. BMC Cell Biol. 2013 Sep 23;14:41. [Content Brief]
- [3]. Tang XH, et al. Combination of bexarotene and the retinoid CD1530 reduces murine oral-cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide. Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8907-12. [Content Brief]
- [4]. Yimiti D, et al. CD1530, selective RARγ agonist, facilitates Achilles tendon healing by modulating the healing environment including less chondrification in a mouse model. J Orthop Res. 2025 Feb;43(2):273-284. [Content Brief]
- [5]. Kim W, et al. A new class of synthetic retinoid antibiotics effective against bacterial persisters. Nature. 2018 Apr 5;556(7699):103-107. [Content Brief]
- [6]. Shirasawa H, et al. Retinoic Acid Receptor Agonists Suppress Muscle Fatty Infiltration in Mice. Am J Sports Med. 2021 Feb;49(2):332-339. [Content Brief]
Keywords
